Home > Publications database > Lifestyle changes and postmenopausal breast cancer risk in women from the European Prospective Investigation into Cancer and Nutrition. > print

001     305587
005     20251101115632.0
024 7 _ |a 10.1186/s13058-025-02148-w
|2 doi
024 7 _ |a pmid:41163053
|2 pmid
024 7 _ |a pmc:PMC12574052
|2 pmc
024 7 _ |a 1465-5411
|2 ISSN
024 7 _ |a 1465-542X
|2 ISSN
037 _ _ |a DKFZ-2025-02246
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Vasson, Fanélie
|b 0
245 _ _ |a Lifestyle changes and postmenopausal breast cancer risk in women from the European Prospective Investigation into Cancer and Nutrition.
260 _ _ |a London
|c 2025
|b BioMed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1761917944_171913
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The risk of breast cancer has been associated with various lifestyle factors, yet the evidence regarding how lifestyle modifications affect this risk remains limited. This study examines the relationship between changes in the Healthy Lifestyle Index (HLI) and postmenopausal breast cancer risk in women participating in the European Prospective Investigation into Cancer (EPIC).HLI scores (ranging from 0 to 16) were computed based on smoking habits, alcohol consumption, body mass index (BMI), and physical activity levels, using data from baseline and follow-up questionnaires, which were separated by a median interval of 10 (IQR: 5.2-12.0) years. Among the 125,746 women included in the analyses, 2,175 developed breast cancer over a median follow-up period of nearly 4 (IQR: 2.9-8.4) years starting from the date of the second lifestyle questionnaire. Cox proportional hazards models were employed to estimate hazard ratios (HRs) and confidence intervals (CIs) for the relationship between changes in HLI and postmenopausal breast cancer risk, analysed both overall and by estrogen receptor (ER) status. Individual components of the HLI were also analysed, with sensitivity analyses addressing potential reverse causation by delaying the start of follow-up by 1 to 3 years.Each unit increase in the HLI-reflecting a healthier lifestyle-was not associated with the overall risk of postmenopausal breast cancer. Among individual components, only a one-unit increase in the BMI score, corresponding to a shift towards a healthier BMI, was inversely associated with overall (HR = 0.936; 95% CI 0.880-0.996) and ER-positive (HR = 0.930; 95% CI 0.865-1.000) postmenopausal breast cancer risks.Lifestyle changes, as measured by the HLI, during mid-adulthood were not significantly associated with the risk of postmenopausal breast cancer. More specifically, the results of this study suggested that a shift towards a healthier BMI may contribute to breast cancer prevention. Further research involving diverse and larger study populations and lifestyle assessments at earlier life stages could provide deeper insights.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Breast cancer
|2 Other
650 _ 7 |a Healthy lifestyle index
|2 Other
650 _ 7 |a Lifestyle changes
|2 Other
650 _ 7 |a Longitudinal
|2 Other
650 _ 7 |a Prospective cohort
|2 Other
650 _ 7 |a Risk
|2 Other
650 _ 7 |a Receptors, Estrogen
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Breast Neoplasms: epidemiology
|2 MeSH
650 _ 2 |a Breast Neoplasms: etiology
|2 MeSH
650 _ 2 |a Postmenopause
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Europe: epidemiology
|2 MeSH
650 _ 2 |a Life Style
|2 MeSH
650 _ 2 |a Risk Factors
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Body Mass Index
|2 MeSH
650 _ 2 |a Surveys and Questionnaires
|2 MeSH
650 _ 2 |a Proportional Hazards Models
|2 MeSH
650 _ 2 |a Exercise
|2 MeSH
650 _ 2 |a Receptors, Estrogen: metabolism
|2 MeSH
650 _ 2 |a Follow-Up Studies
|2 MeSH
700 1 _ |a Matta, Komodo
|b 1
700 1 _ |a Biessy, Carine
|b 2
700 1 _ |a S Antoniussen, Christian
|b 3
700 1 _ |a Fournier, Agnès
|b 4
700 1 _ |a Marques, Chloé
|b 5
700 1 _ |a Cadeau, Claire
|b 6
700 1 _ |a Le Cornet, Charlotte
|0 P:(DE-He78)2d4cac0f4bf270325b98fe07036dc6c6
|b 7
|u dkfz
700 1 _ |a T Fortner, Renée
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Schulze, Matthias B
|b 9
700 1 _ |a Sieri, Sabina
|b 10
700 1 _ |a Panico, Salvatore
|b 11
700 1 _ |a Tumino, Rosario
|b 12
700 1 _ |a Ricceri, Fulvio
|b 13
700 1 _ |a Masala, Giovanna
|b 14
700 1 _ |a Hiensch, Anouk E
|b 15
700 1 _ |a Monninkhof, Evelyn M
|b 16
700 1 _ |a Agudo, Antonio
|b 17
700 1 _ |a Guevara, Marcela
|b 18
700 1 _ |a Colorado-Yohar, Sandra M
|b 19
700 1 _ |a Sánchez, Maria-José
|b 20
700 1 _ |a Llorente, Adrian
|b 21
700 1 _ |a Tin Tin, Sandar
|b 22
700 1 _ |a Jackson, Isobel G
|b 23
700 1 _ |a Gunter, Marc J
|b 24
700 1 _ |a Botteri, Edoardo
|b 25
700 1 _ |a Ferrari, Pietro
|b 26
700 1 _ |a Dossus, Laure
|b 27
773 _ _ |a 10.1186/s13058-025-02148-w
|g Vol. 27, no. 1, p. 192
|0 PERI:(DE-600)2041618-0
|n 1
|p 192
|t Breast cancer research
|v 27
|y 2025
|x 1465-5411
909 C O |o oai:inrepo02.dkfz.de:305587
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)2d4cac0f4bf270325b98fe07036dc6c6
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2025
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BREAST CANCER RES : 2022
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-04-10T15:36:03Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-04-10T15:36:03Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-04-10T15:36:03Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-05
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-05
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b BREAST CANCER RES : 2022
|d 2024-12-05
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-05
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-05
920 1 _ |0 I:(DE-He78)C180-20160331
|k C180
|l Krebsepidemiologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C180-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21